TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.1, ss.16-26, 2017 (SCI-Expanded, Scopus, TRDizin)
Objective: Tyrosine kinase inhibitors (TKIs) have changed the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia (CML). Therefore, we aimed to evaluate the effect of TKIs on allo-HSCT in CML.